Intensity Therapeutics, Inc.

Good morning and welcome to the Intensity Therapeutics second quarter 2023 conference call and webcast. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference call over to our host, Michael Miller of RX Communications. Please go ahead.

Thank you, operator. Good morning, and thank you for joining the Intensity Therapeutics conference call to review the financial and operating results for the second quarter ended June 30th, 2023. I'm joined today by Lewis H. Bender, Founder and Chief Executive Officer, and John Wesolowski, Chief Financial Officer. As a reminder, this conference call contains forward-looking statements within the meaning of the federal securities laws. The company's actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that might cause actual results to differ materially from those in the forward-looking statements is contained in the company's periodic reports filed with the Securities and Exchange Commission. The information presented today is time sensitive and is accurate only as the date of this call, August 14th, 2023. If any portion of this call is being rebroadcast, retransmitted, or redistributed at a later date, Intensity Therapeutics will not be reviewing or updating this material. I would now like to turn the call over to Mr. Bender. Please go ahead, Lou.

Thank you, Mike. Good morning, everyone, and thank you for joining us today. We appreciate your interest in this inaugural Intensity Therapeutics earnings call. As Mike mentioned, I'm Lew Bender, and I'm the founder and CEO of Intensity Therapeutics. On today's call, we plan to review our financials for the quarter, discuss the origins of our novel technology, explain the science behind our locally delivered drug, and why our product candidate has the potential to succeed in metastatic disease, such as sarcoma, as well as local disease in areas such as breast cancer. I shall also discuss our programs to treat sarcoma and early stage breast cancer, review our quarterly business results, provide details into our current development activities, and our objective today really is to explain how our lead drug, INT230-6, could be a very new weapon in the war on cancer. Now, as everyone knows, the financing environment for healthcare has been and continues to be challenging. I believe that there have been only seven biotech IPOs with a raise of over 20 million so far in 2023. And that being said, I believe investors will respond to data. And the data that we presented in Q2 at ASCO was strong. And as a result, we were able to complete an upsized oversubscribed IPO at the top of the range. I'm very excited by that. I'm even more relieved that we were able to do it. But to go into more detail and about our financial for Q2, I shall turn the call over to John Wieselowski, our CFO and principal accounting officer.